The notion that the PD1:PDL1 axis contributes to immune suppression in the tumor microenvironment has been established in both animal models and in cancer patients.27, 28, 29 Antibodies that disrupt either PD1 or PDL1 have had tremendous impact in patient outcomes, demonstrating the robust anti-tumor immune effects of these checkpoint inhibitors in an in vivo setting. Here, CD274 is linked to cancer.